IgE responses to bluetongue virus (BTV) serotype 11 after immunization with inactivated BTV and challenge infection

Odeón, Anselmo; Gershwin, Laurel J.; Osburn, Bennie

doi:10.1016/s0147-9571(98)00031-9

Cited by 12 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in humans and animals reported by others have identified IgE anti-virus antibodies in several viral infections including respiratory syncytial virus (RSV) 8 , 9 , parainfluenza 10 , HTLV-1 11 , Puumala virus 12 , HSV-1, HSV-2, and Epstein-Barr virus 13 , and blue tongue virus in cattle 14 .…”

Section: Introductionmentioning

confidence: 99%

Long Term Persistence of IgE Anti-Influenza Virus Antibodies in Pediatric and Adult Serum Post Vaccination with Influenza Virus Vaccine

Smith‐Norowitz¹,

Wong²,

Kusonruksa³

et al. 2011

Int. J. Med. Sci.

View full text Add to dashboard Cite

The production of IgE specific to different viruses (HIV-1, Parvovirus B19, Parainfluenza virus, Varicella Zoster Virus), and the ability of IgE anti-HIV-1 to suppress HIV-1 production in vitro, strongly suggest an important role for IgE and/or anti viral specific IgE in viral pathogenesis. Nevertheless, the presence and persistence of IgE anti-Influenza virus antibodies has not been studied. Total serum IgE and specific IgE and IgG anti-Influenza virus antibodies were studied in children (N=3) (m/f 14-16 y/o) and adults (N=3) (m/f, 41-49 y/o) 2-20 months after vaccination with Influenza virus (Flumist® or Fluzone®), as well as in non-vaccinated children (N=2). (UniCAP total IgE Fluoroenzymeimmunoassay, ELISA, Immunoblot). We found that serum of vaccinated children and adults contained IgE and IgG anti-Influenza virus antibodies approaching two years post vaccination. Non-vaccinated children did not make either IgE or IgG anti-Influenza antibodies. Similar levels of IL-2, IFN-γ, IL-4, and IL-10 cytokines were detected in serum of vaccinated compared with non vaccinated subjects (p>0.05), as well as between vaccinated adults compared with vaccinated children and non vaccinated subjects (p>0.05). Vaccinated children and adults continue to produce IgE anti-Influenza virus antibodies long term post vaccination. The long term production of IgE anti-Influenza virus antibodies induced by vaccination may contribute to protective immunity against Influenza.

show abstract

Section: Introductionmentioning

confidence: 99%

Long Term Persistence of IgE Anti-Influenza Virus Antibodies in Pediatric and Adult Serum Post Vaccination with Influenza Virus Vaccine

Smith‐Norowitz¹,

Wong²,

Kusonruksa³

et al. 2011

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…,Martinelle et al (2011),Monaco et al (2004a,b,c),Odeon et al (1999),Parsonson et al (1994Parsonson et al ( , 1987a, Dal Pozzo et al (2009), Richards et al (1988), Roeder et al (1991), Schlafer et al (1990), Van der Sluijs et al (2012), Squire (1989), Thomas et al (1985), Waeckerlin et al (2010), Waldvogel et al (1992a); Waldvogel et al (1992b), Whetter et al Batten et al (2014, 2012), Belbis et al (2013), Breard et al (2011), Caporale et al (2014), Coetzee et al (2013), Planzer et al (2011), Vogtlin et al 1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations…”

mentioning

confidence: 99%

Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bluetongue

More¹,

Bicout²,

Bøtner³

et al. 2017

EFS2

View full text Add to dashboard Cite

A specific concept of strain was developed in order to classify the BTV serotypes ever reported in Europe based on their properties of animal health impact: the genotype, morbidity, mortality, speed of spread, period and geographical area of occurrence were considered as classification parameters. According to this methodology the strain groups identified were (i) the BTV strains belonging to serotypes BTV-1-24, (ii) some strains of serotypes BTV-16 and (iii) small ruminant-adapted strains belonging to serotypes BTV-25, -27, -30. Those strain groups were assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7, Article 5 on the eligibility of bluetongue to be listed, Article 9 for the categorisation according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related to bluetongue. The assessment has been performed following a methodology composed of information collection, expert judgement at individual and collective level. The output is composed of the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported. The strain group BTV (1-24) can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, while the strain group BTV-25-30 and BTV-16 cannot. The strain group BTV-1-24 meets the criteria as in Sections 2 and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in points (b) and (e) of Article 9(1) of the AHL. The animal species that can be considered to be listed for BTV-1-24 according to Article 8(3) are several species of Bovidae, Cervidae and Camelidae as susceptible species; domestic cattle, sheep and red deer as reservoir hosts, midges insect of genus Culicoides spp. as vector species.

show abstract

“…With the identification of some of the antigenic epitopes of various BTV proteins (Wang et al, 1972; Geysen et al, 1985; Fukusho et al, 1987; Gould et al, 1988a, 1994; Grieder and Schultz, 1989; Geysen, 1990; Li and Yang, 1990, 1992; Marshall and Roy, 1990; Mecham and Jochim, 1990; Eaton et al, 1991; Rossitto and MacLachlan, 1992; Du Plessis et al, 1994, 1995; Schoehn et al, 1997; Nagesha et al, 2001), BTV immunity has only been studied partially in the last two decades because of lack of supporting funding and reliable immune assays (Jeggo and Wardley, 1982a,b; Gibbs et al, 1983; Jeggo et al, 1983; Campbell and Grubman, 1985; Stott et al, 1985; Fukusho et al, 1987; Huismans et al, 1987a; Marshall and Roy, 1990; Martyn et al, 1991; Li and Hwang, 1992; Jones et al, 1996, 1997; Lin and Zhou, 1996; Wade-Evans et al, 1996; Odeon et al, 1999; Prasad and Minakshi, 1999; DeMaula et al, 2000; Roy, 2003). With the recent development of more reliable immune assays and microarrays, we have found that BTV can induce inflammatory cytokine expression in immortalized human kidney, lung, and liver cells and subsequently kill the infected cell with cell line-dependent severity.…”

Section: Inflammatory Mediators Are Elevated During Btv Infectionmentioning

confidence: 99%

Oncolytic Bluetongue Viruses: Promise, Progress, and Perspectives

Li¹

2011

Front. Microbio.

View full text Add to dashboard Cite

Humans are sero-negative toward bluetongue viruses (BTVs) since BTVs do not infect normal human cells. Infection and selective degradation of several human cancer cell lines but not normal ones by five US BTV serotypes have been investigated. We determined the susceptibilities of many normal and human cancer cells to BTV infections and made comparative kinetic analyses of their cytopathic effects, survival rates, ultra-structural changes, cellular apoptosis and necrosis, cell cycle arrest, cytokine profiles, viral genome, mRNAs, and progeny titers. The wild-type US BTVs, without any genetic modifications, could preferentially infect and degrade several types of human cancer cells but not normal cells. Their selective and preferential BTV-degradation of human cancer cells is viral dose–dependent, leading to effective viral replication, and induced apoptosis. Xenograft tumors in mice were substantially reduced by a single intratumoral BTV injection in initial in vivo experiments. Thus, wild-type BTVs, without genetic modifications, have oncolytic potentials. They represent an attractive, next generation of oncolytic viral approach for potential human cancer therapy combined with current anti-cancer agents and irradiation.

show abstract

IgE responses to bluetongue virus (BTV) serotype 11 after immunization with inactivated BTV and challenge infection

Cited by 12 publications

References 27 publications

Long Term Persistence of IgE Anti-Influenza Virus Antibodies in Pediatric and Adult Serum Post Vaccination with Influenza Virus Vaccine

Long Term Persistence of IgE Anti-Influenza Virus Antibodies in Pediatric and Adult Serum Post Vaccination with Influenza Virus Vaccine

Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bluetongue

Oncolytic Bluetongue Viruses: Promise, Progress, and Perspectives

Contact Info

Product

Resources

About